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ABSTRACT 
Background and objectives. Between 2004 and 2012, five rounds of mass drug 
administration (MDA) of praziquantel has been rolled out for the control of schistosomiasis 
in Burkina Faso, West Africa. The aim of this study is to analyse the effect of MDA of 
praziquantel on the prevalence and intensity of infection of schistosomiasis in Burkina. 
Methods. A longitudinal survey was conducted from 2008 to 2013 at 22 sentinel sites across 
Burkina in order to estimate the presence of Schistosoma haematobium infection. In addition, 
in 2013, a cross sectional study of S. haematobium and S. mansoni in school children aged 7 
to 11 years was conducted in the same sites. Standardised diagnostic techniques were used to 
analyse stool (Kato Katz) and urine (filtration) samples for the presence and number of S. 
mansoni and S. haematobium eggs, respectively. 
Results. The findings from the longitudinal survey show a reduction in the median 
prevalence of S. haematobium from 16% to 3%. The cross-sectional survey shows that 13 of 
22 sentinel sites still had a prevalence of schistosomiasis >1%, with a prevalence of 56% at 
the highest. The prevalence of schistosomiasis was higher among boys and older children. 
Conclusions. The impact evaluation of five years of MDA of praziquantel in Burkina Faso 
from 2004 to 2012 suggests that treatment has had a significant impact on reducing the 
prevalence of schistosomiasis. However, the prevalence of schistosomiasis still remains high 
in a third of the sentinel sites and, in line with World Health Organization (WHO) guidelines, 
increased frequency of drug distributions, alongside health education and improvement of 
sanitation and access to improved water sources, is needed. Further and more detailed studies 
are needed in order to determine the effect of control strategies and future priorities for the 
control of schistosomiasis in Burkina Faso. 
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INTRODUCTION 
Neglected tropical diseases 
Neglected tropical diseases (NTDs) are a group of infectious diseases that cause debilitating 
suffering among millions of the poorest people in the world (1). NTDs typically thrive in 
resource-limited societies in tropical climates, and have for a long time been more or less 
absent from the international public health agenda. The term “NTDs” was developed as a 
reaction to the understatement of these diseases in the United Nations’ Millenium 
Development Goal number six; ”combat HIV/AIDS, malaria and other diseases” as well as 
the establishment of the Global Fund to fight AIDS, tuberculosis and malaria. Pioneer 
scientists showed in a series of publications how these other diseases for many years have 
been overshadowed by the battle against the “three big” HIV/AIDS, malaria and tuberculosis 
(2-4). Gradually, though, NTDs have become a priority on the global health agenda, and the 
battle against these diseases has gained momentum and resources (5, 6). 
 
In the mid-2000s, the fight against NTDs saw a paradigm shift as the World Health 
Organization (WHO) moved away from the traditional disease-centered approach to a 
broader response strategy to the health needs of low- and middle-income countries. In 2005, 
this resulted in the establishment of the WHO Department of Control of Neglected Tropical 
Diseases (6). Several global initiatives followed that aimed to increase the attention and 
awareness of NTDs, including the Global Network for Neglected Tropical Diseases and The 
Task Force for Global Health. Together, these efforts have culminated in the development of 
elimination programmes such as the Global Programme to Eliminate Lymphatic Filiariasis 
(GPELF) and the African Programme for Onchocerciasis Control (APOC) (7-11). In 2007, in 
order to advance the growing scientific literature on NTDs, the Public Library of Science 
(PLoS) launched PLoS Neglected Tropical Diseases; an open-access and non-profit journal 
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funded by the Bill & Melinda Gates foundation (12). 
 
WHO have identified 17 neglected tropical diseases (Table 1), of which two are targeted for 
eradicationa - dracunculiasis and yaws, and four are targeted for eliminationb - trachoma, 
human African trypanosomiasis, leprosy and lymphatic filariasis (6). Moreover, WHO have 
identified some states as target countries for elimination of schistosomiasis (13). 
 
Table 1. The etiology, epidemiology and main control strategies of the most prevalent 
neglected tropical diseases (WHO 2013). 
Disease Agent Number of infected Number at-risk Main control strategy 
Soil-
transmitted 
helminths 
Helminth 2 billion >2 billion MDA 
Schistosomiasis 
(bilharziasis) Helminth 250 million 779 million MDA 
Trachoma Bacteria 150 million  229 million SAFE strategy 
Dengue Virus 50-100 million >2.5 billion Vector control (mosquitos) 
Food-borne 
trematode 
infections 
Helminth 56 million infected Not known MDA 
Cysticercosis Helminth 
>30 million; >10 
million with 
neurocysticercosis 
Not known MDA, human and veterinary prevention 
Onchocerciasis Helminth 25 million 125 million MDA 
Lymphatic 
filariasis Helminth 20 million 1.4 billion MDA 
MDA: mass drug administration; SAFE: Surgery (S), antibiotics (A), facial cleanliness (F) 
and environmental change (E). 
                                                            
a A permanent reduction to zero of the worldwide prevalence of an infectious disease; 
continued measures are no longer required. 
b A reduction to zero of the number of new cases of an infectious disease in a defined 
geographic area; continued intervention or surveillance measures are required. 
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Schistosomiasis 
Schistosomiasis is a common cause of acute and chronic disease, especially in sub-Saharan 
Africa (14). Over 200 million people are estimated to be infected worldwide, of whom only 
half are symptomatic. Approximately 20 million are estimated to have severe complications 
of the disease (15), and among the infected, around half are estimated to be school-age 
children, typically 5-14 years of age (16). 
 
Mainly five species of schistosomes are pathogenic to humans: Schistosoma haematobium 
that causes urogenital schistomiasis, and S. japonicum, S. intercalatum, S. mansoni and S. 
mekongi that cause intestinal schistomiasis (17). S. haematobium and S. mansoni are 
prevalent mainly in sub-Saharan Africa and along the Nile, whereas S. japonicum and S. 
mekongi are endemic in East Asia. S. intercalatum is mainly prevalent in focal areas of 
equatorial Africa (Figure 1) (18). 
 
Figure 1. The geographic distribution of schistosomiasis (WHO, 2010). 
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The life cycle of schistosomes 
Schistosomes are a group of trematode, parasitic worms, or helminths, with a two-stage life 
cycle (Figure 2) (18-20). Humans get infected through contact with freshwater containing 
infectious larvae named cercariae. The larvae penetrate intact skin, and develop into 
immature worms (schistosomulae). The schistosomulae get carried with the lymph and blood 
to the right side of the heart, and subsequently to the lungs, where they migrate across the 
pulmonary capillaries to the left side of the heart. They are thereafter carried with the arterial 
blood flow to the portal vein of the liver where they mature into adult worms. This process 
may take up to eight weeks. A pair of mature female and male worms then make their way 
from the liver, against the venous blood stream, to perivesical (S. haematobium) or 
mesenterical (S. mansoni and other species) venous plexuses. 
 
Within these small venules, the female worm can lay up to several hundreds of eggs a day for 
up to several decades (21, 22). The eggs penetrate the vessel wall and migrate into the organ 
tissue (18-20). The eggs that reach the lumen of either the bladder (S. haematobium) or the 
colon (S. mansoni), are excreted in the urine and stool, respectively, whereas the remaining 
eggs get trapped in the tissue, causing inflammation and potentially organ damage. Excreted 
eggs hatch when they reach fresh water and miracidia (immature larvae) are released from 
within the eggs, actively seek out and penetrate fresh water snails (intermediate hosts). The 
miracidia multiply asexually within the snail, a process that may take from four to six weeks, 
before they end up as cercarial larvae. Cercariae finally leave the snail in search of a 
definitive human host, thereby completing the cycle (Figure 2). 
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Figure 2. The schistosome life cycle (Centers for Disease Control (CDC) 2012). 
 
Clinicopathological presentation 
The main burden of the schistosomal disease is caused by chronic inflammation due to the 
schistosome eggs that remain in the tissue. Chronic schistosomiasis occurs most commonly in 
endemic areas, where individuals get continuously exposed and re-exposed to schistosomes 
over many years, often already from early childhood (23). Most people infected with 
schistosomes show no or few symptoms, and many may have non-specific symptoms such as 
fatigue, impaired cognitive development and reduced work capacity. However, severe disease 
frequently develops in heavily infected individuals, although the severity probably depends 
on factors such as the schistosome genetics and the human immunogenetic profile (18-20). 
 
Acute infection may present shortly after skin penetration as cercarial dermatitis, and after a 
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few weeks to months as Katayama fever (24, 25). Both forms are most common in travellers, 
although infection with S. japonicum commonly presents acutely also in people living in 
endemic areas. The acute forms of schistosomiasis are thought to represent allergic reactions 
to the various stages of the parasite (25). In some cases, disease may be caused by eggs 
dislodging from the most common parasite locations in the body, to so-called ectopic foci 
such as the lungs and central nervous system (26). 
 
Diagnosis 
The diagnosis of schistosomiasis is traditionally made by microscopic detection and 
quantification of eggs in urine (S. haematobium) or faeces (S. mansoni and S. japonicum). 
Specific concentration methods, Kato-Katz for stool (27) and filtration of urine (28, 29), are 
used in order to increase the probability of detecting any present eggs. In field settings, WHO 
suggests to use urine dipsticks to detect haematuria in high-endemic areas. 
 
Serological assays of circulating antibodies to schistosomal antigens has been used to aid 
diagnosis in travellers; however, these tests have until now been of little use in high-endemic 
settings as this method does not distinguish between prior and ongoing infection (30). 
Recently, a point-of-care circulating cathodic antigen (CCA) assay has been developed to 
detect both S. mansoni antigens in urine (31). In fact, studies indicate that this test may prove 
more sensitive than the Kato-Katz method for diagnosing schistosomiasis in endemic 
settings, and allows for testing without the collection of stool samples (32, 33). Eggs or 
worms may also be detected by examining tissue biopsies (34, 35), and DNA may be detected 
in serum, faeces or urine, although the use of the latter tests is limited by the relatively high 
costs and irregularities in egg excretion (36-38). Ultrasound, PET-scans and other 
radiographic methods may be used to reveal organ damage (39). 
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Treatment and control strategies 
Praziquantel is the drug of choice for the treatment of schistosomiasis and the number of 
tablets may be easily calculated using a tablet-pole which visualises a dose corresponding to 
at least 40 mg/kg based on the individual’s height. Advocacy efforts have led to a reduction 
in the price of praziquantel in most countries, and large quantities of tablets are now being 
donated by pharmaceutical companies (29, 30). 
 
WHO promotes five main public health interventions in the battle against schistosomiasis: 
preventive chemotherapy, vector control, access to safe drinking-water, basic sanitation, 
hygiene services and health education (6). WHO has proposed a plan for the control and 
elimination of schistosomiasis, and states that elimination may be possible through the main 
control interventions and improved coordination of stakeholders (5). Of the above-mentioned 
interventions, preventive chemotherapy with praziquantel has been selected as the most 
important tool due to its cost-effectiveness, safety and rapid impact (14). Snail control, on the 
other hand, is considered less cost-effective and can be harmful to the environment (17). 
 
Recently, unprecedented drug donations of praziquantel, as well as the proven successes of 
mass treatment programmes, such as those initiated by the Schistosomiasis Control Initiative, 
have reinforced WHO policies (13, 30, 40). Mass drug administration (MDA) consists of 
distributing drugs to the entire population in endemic areas, regardless of individual 
diagnosis. Drug administration can be implemented community-wide through for example 
community health workers that go from house-to-house, or through campaigns in specific 
population groups, such as school-age children at primary schools. WHO recommends 
treatment frequency based on the prevalence of schistosomiasis, determined by country 
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mapping or by sentinel sitesc (29) (Table 2). 
 
Table 2. Preventive chemotherapy strategies for the control of schistosomiasis (WHO 2011). 
Category Prevalence school-age children Recommended strategy 
High risk 
community 
≥50% by parasitological 
methods (intestinal and 
urogenital schistosomiasis) 
or 
≥30% by questionnaire for 
visible haematuria (urogenital 
schistosomiasis) 
Treat all school-age 
children (enrolled and 
not enrolled) once a 
year 
Also treat adults 
at risk from 
special groups to 
entire 
communities in 
endemic areas) 
Moderate-
risk 
community 
≥10% but <50% parasitological 
methods (intestinal and 
urogenital schistosomiasis) 
or 
<30% by questionnaire for 
visible haematuria (urogenital 
schistosomiasis) 
Treat all school-age 
children (enrolled and 
not enrolled) once 
every 2 years 
Also treat adults 
considered to be 
at risk (special 
risk groups only) 
Low-risk 
community 
<10% by parasitological 
methods (intestinal and 
urogenital schistosomiasis) 
Treat all school-age 
children (enrolled and 
not enrolled) twice 
during their primary 
schooling age 
Praziquantel 
should be 
available in 
dispensaries and 
clinics for 
treatment of 
suspected cases  
 
The national NTD control programme of Burkina 
The Schistosomiasis Control Initiative (SCI) was established in 2002 with funding from the 
Bill & Melinda Gates Foundation (BMGF) and is based at Imperial College in London. SCI 
selected Burkina as one of the first countries to prove the concept of feasible nationwide 
MDA against schistosomiasis (41). The control strategies were to be implemented through 
the national Ministry of health, and the target was set out to treat at least 75% of school-age 
children and other populations at risk. The MDA would include both praziquantel against 
schistosomiasis and benzimidazoles against soil-transmitted helminthes (STH); an integrated 
                                                            
c Sentinel sites: randomly selected primary schools in schistosomiasis-endemic areas in which 
school children are followed prior to each treatment round 
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approach supported by the evidence of co-endemicity of these diseases. Continuous 
monitoring and evaluation were essential in order to track programme targets (14). 
 
Study objective 
The aim of this study is to analyse the effect of five years of MDA of praziquantel on the 
prevalence and intensity of infection of schistosomiasis in Burkina Faso. 
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METHODOLOGY 
Burkina Faso 
Burkina Faso is a landlocked country in West Africa with a population of close to 16 million 
people (Figure 3). The majority of the population lives in the south and central parts of the 
country, including the capital city, Ouagadougou. Up to 80 % of the population works in the 
agricultural section (42) . The country is currently rated 183 of 187 countries in the world on 
the Human Development Index (HDI), and the poverty rate is estimated to be 66 % of the 
population (43). Primary education is free, but not compulsory. In 2013, the national primary 
school enrolment rate was 81%; however, there are large regional and gender-based 
variations, with some areas showing primary school enrolment rates of girls as low as 40 %. 
 
Figure 3. Burkina Faso is a land-locked country situated in West Africa. 
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Youth illiteracy rates are currently estimated to be 28%, compared to about 70% on average 
for sub-Saharan Africa (44). The country has a three level health system; a central Ministry of 
health, 13 regional health departments and 63 health districts (45). Approximately 6 % of the 
gross domestic product is spent on health care, and there are less than one health care 
professional per 1,000 inhabitants (46). 
 
Burkina, a prior French colony, has gone through several governmental changes since it 
gained its independency in 1960. The population is made up of a number of tribes, of which 
the Mossi are the most common. The country consists of two main ecological zones: a 
sandstone massif in the southwest and peneplaind in the rest of the country. Several major 
rivers flow through the country; however, only the Black Volta and the Komoé are perennial. 
Average temperatures are in general highest in the north, with a progressively milder climate 
towards the south (47). 
 
Pre- and post-MDA surveys 
Pre-treatment mapping data prior to 2004 suggest that all 63 health districts were endemice 
for schistosomiasis. From 2004 to 2012, independent of the respective district-level 
prevalence, the country chose to roll out five biennial rounds of MDA of praziquantel to 
school age children (48). School attendance rates proved to be less than 50%, and measures 
were taken to reach non-enrolled school-age children. The first round of MDA was financed 
by BMGF, while the second round of treatment, which took place between 2006 and 2008 
and targeted more than 2.5 million school-age children in nine districts, was supported by 
SCI and the United States Agency for International Development (USAID). In September 
                                                            
d Peneplain: a gently undulating, almost featureless plain, believed to be the final stage of the 
geomorphic cycle of landform evolution. 
e Endemic: The constant presence of diseases or infectious agents within a given geographic 
area or population group (CDC). 
16 
2010, USAID awarded FHI 360 two five-year term agreements to administer the End 
Neglected Tropical Diseases (END) in Africa and END in Asia programmes (49). 
 
In order to evaluate the impact of treatment on population health and the prevalence of 
schistosomiasis and soil-transmitted helminths, cohorts of school-age children in sentinel 
schools were examined before each treatment round (50). The results have allowed the 
country to evaluate and, if necessary, adjust their control strategies according to guidelines 
(51). The most recent survey was conducted in 2013, with financial and technical support 
provided by USAID, Helen Keller International, FHI 360 and END in Africa (52). 
 
Data collection and analysis 
During six weeks of January and February 2014, the authors studied the methodology and in-
country conditions for the most recent sentinel site survey conducted in Burkina. Information 
and data were gathered through meetings with national NTD staff within the Ministry of 
health, including the national NTD coordinator, studies of internal and official survey 
documents and reports, and meetings with laboratory staff that had contributed to the survey. 
Survey results and challenges were discussed and analysed throughout these meetings. 
 
Sentinel site survey methodology 
A longitudinal cohort study of primary school sentinel sites selected from 11 of the 13 
regions of Burkina was conducted from February to June 2013. Two sentinel sites were 
selected in each of the 11 regions, except for the region of Hauts-Bassins, where three 
sentinel sites were selected, and Cascades, where only one was included. In addition to the 
2013 study, annual surveys have been conducted since 2008, apart from in 2011 from when 
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no data is available due to limited resources, and in 2012, when only a minority of the 
sentinel sites was studied. 
 
Thirty-two school children from each age group between 7 and 11 years were selected to 
participate in the study, in total 160 pupils from each sentinel site. The sample sizes were 
calculated using an average intensity of S. haematobium infection and expected reduction 
predicted by the software EpiSchisto (53). A research team from the national NTD 
programme, equipped with a mobile laboratory, collected and analysed samples from each of 
the selected sites. When roads were in good enough condition, the team would drive the 
mobile laboratory to the sentinel school and samples were examined on site. When road 
conditions were poor, due to rain and other weather constraints, the team would set up the 
laboratory in a nearby village where samples would be analysed after being collected at the 
respective sentinel site. All samples were examined the same day they were collected, 
regardless of the laboratory’s location. 
 
The 32 children from each age group were selected by dividing the total number of children 
in each age group present at the school by 32; e.g. if 320 children were present in one age 
group, every tenth child would be selected. One of the laboratory technicians would 
randomly select which of the first three children they were to start counting from, and every 
child selected at the given interval would be asked to provide a sample. The selected children 
were given two pots, one for stool and another for urine, and were instructed on how to 
collect the samples. The samples were collected between noon and 2 pm. This routine 
continued until all the samples from each school were collected and analysed. 
 
The Kato-Katz technique was used to detect S. mansoni eggs in the stool samples, and 
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intensity of infection was estimated by calculating the number of schistosome eggs per gram 
of feces. For S. haematoubium, the urine was evaluated for haematuria using dipsticks, and 
thereafter examined for schistosome eggs by filtering 10 mL of urine per child. Two trained 
laboratory technicians examined every sample once. 
 
Ethical considerations 
The study was granted approval by the National Ethics Committee in Burkina, and for every 
school that was selected consent was obtained from the principal on behalf of the children. 
This study did not pose any harm or risk to the participants, and all school-age children were 
offered treatment with praziquantel in the following MDA. 
 
Statistical analysis 
All data was plotted into Excel before analysed using SPSS v.17 for statistical analysis. 
Descriptive statistics and results of some comparative analyses were presented. The authors 
could unfortunately not access the original data set were therefore not able to perform further 
analysis at the time of this study. 
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RESULTS 
Prevalence of schistosomiasis in Burkina Faso, 2013 
In total, 3,520 school-age children between 7 and 11 years provided samples for the survey. 
The number of children per age group ranged from 699 among 10 year olds to 709 among 9 
year olds. Fifty per cent of the total population were girls. Figure 4 shows the prevalence of 
schistosomiasis based on gender being equally distributed among the age groups. The overall 
prevalence of schistosomiasis in boys and girls in sentinel sites was 9%, and the prevalence 
among girls was significantly lower than among boys (p <0.05). 
 
Figure 4. Prevalence of schistosomiasis (S. haematobium and S. mansoni) according to 
gender and age in Burkina Faso, 2013. 
 
Intensity of infection 
Figure 5 shows the distribution of intensity of infection according to gender. Boys had 
heavier intensity of infection then their female counterparts, and in total, 11 year olds had 
Prevalence 
Age group 
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heavier infections than other age groups. Ninety-one per cent of 11 year olds with a positive 
sample had a moderate or heavy intensity infection. 
 
Figure 5. Intensity of schistosome infection according to gender in Burkina Faso, 2013. 
 
Figure 6 summarises the results from the cross-sectional survey of schistosomiasis in Burkina 
Faso in 2013. The prevalence map shows that areas with high prevalence are found especially 
in the northern and eastern parts of the country, whereas central and southern areas have a 
lower prevalence. The prevalence of schistosomiasis in the region of Sahel in Burkina is 
21%, making it the region with the highest prevalence in the country. 
  
n 
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Figure 6. The estimated prevalence of schistosomiasis in Burkina Faso, 2013 (54). 
 
Longitudinal prevalence from 2008 to 2013 
Table 3 shows the prevalence of S. haematobium infection from 2008 until the most recent 
sentinel site survey results from 2013. From 2008 to 2013, a significant reduction was 
observed in the prevalence of S. haematobium infection among the examined school-age 
children in sentinel sites (p <0.05). Two of the sentinel sites saw an increase in prevalence, 
most markedly in Lioulgou in the Centre East region. 
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Table 3. The prevalence of S. haematobium infection from 2008 to 2013, longitudinal 
sentinel site surveys in Burkina Faso. 
REGION SENTINEL SITE 
Prevalence of 
S. haematobium (%) Reduction in % 
2008 2009 2010 2013 2008-2013 
Boucle du 
Mouhoun 
Tikan 14.4 5.6 3.0 12.5 13.2 
Tiao 0.0 0.0 0.0 0.0 0.0 
Centre Est Nianle 15.0 10.3 3.1 12.5 16.7 Lioulgou 14.4 22.0 21.8 56.3 -290.6 
Centre Nord Sidogo 10.0 0.0 0.0 5.6 43.8 Tougouri 16.3 2.2 20.4 5.0 69.3 
Centre Ouest Soala 16.9 1.3 0.6 0.0 100.0 Bayandi Palogo 23.1 0.0 8.2 0.0 100.0 
Centre Sud Badongo 29.4 0.0 3.5 2.5 91.5 Mediga 13.8 0.7 2.9 2.5 81.9 
Nord Doure 11.3 0.0 0.0 0.0 100.0 Koumbri 23.1 1.3 0.7 1.9 91.9 
Hauts-Bassins 
Kari 1.7 0.0 0.0 0.0 100.0 
Panamasso 17.9 32.3 34.5 25.0 -39.7 
Noumousso 1.3 0.5 0.4 0.0 100.0 
Sahel Windou/Lerbou 38.8 33.3 23.8 20.6 46.8 Dori B 55.0 15.0 27.7 20.6 62.5 
Sud Ouest Gora 0.0 0.0 0.0 0.0 0.0 Bawan 11.3 0.0 0.0 0.6 94.4 
Est Nagbingou 22.5 58.7 53.1 17.5 22.2 Sampieri 25.0 8.9 21.5 18.8 24.7 
Cascades Douna 20.4 4.3 8.4 0.0 100.0 
MEDIAN   15.7 1.3 3.0 2.5 66.0 
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DISCUSSION 
Since the turn of the century, the control of NTDs has gained increased attention and global 
momentum, opening up for unprecedented opportunities to end the suffering caused by these 
highly prevalent and, still, neglected diseases. In 2004, Burkina Faso was selected as one of 
the first countries to prove the concept of a nationwide NTD control programme through 
MDA of praziquantel. The findings from the longitudinal sentinel site surveys prior to each 
of the five rounds of MDA rolled out between 2004 and 2012 suggest that the prevalence of 
schistosomiasis has been significantly reduced from more than 17% in 2008 to less than 10% 
in 2013. 
 
The findings from the surveys in Burkina are in line with results from a number of studies of 
MDA of praziquantel in other African countries (55-58). A study from Mali found a 30% 
decrease in prevalence over six years of MDA (56), whereas two studies from Uganda found 
a marked decrease in both prevalence and intensity of S. mansoni infection (55, 57). MDA of 
praziquantel may lead to reduced intensity of infection, although the impact on prevalence 
may vary between different age groups (58). In our study, longitudinal data on the intensity 
of infections was not available, and the impact of MDA on intensity of infection could 
therefore not be determined. 
 
Although the district level prevalence of schistosomiasis has been reduced, the majority of 
sentinel sites still show proof of schistosomiasis in the school-age population. Moreover, one 
school in the Centre East region saw an increase in prevalence from 14 to 56%. One possible 
explanation for this could be the recent increase in population size, alongside newly 
developed irrigation systems (59) which may increase transmission rates (15). If the results 
from this site are excluded, the average prevalence would be reduced from 19 to 7%.  
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Both the prevalence and intensity of infection of schistosomiasis were significantly higher 
among boys than among girls. One possible explanation might be that boys due to social 
norms or traditions are more often in contact with water than their female counterparts, 
thereby making them more exposed to cercariae. A study conducted in Mali observed that the 
water related activities consisted of helping parents fishing, growing vegetables and other 
domestic activities (60). Also, in line with previous studies, the results found a higher 
prevalence among 11 year olds compared with the other age groups (10). 
 
This survey has several limitations. The methodology for selecting sentinel sites was not 
described, and the validity of the results may therefore not be determined. The regions in 
Burkina are vast, and it is possible that the sentinel sites might not be representative for the 
overall population. If the selected sentinel sites are located far from schistosome transmission 
sites, the prevalence of schistosomiasis in the district could in reality be higher than indicated. 
Moreover, no sentinel sites have been chosen in the regions containing the two largest cities, 
Ouagadougou and Bobo-Dioulasso, with a joint population of 2.1 million inhabitants. 
Further, the sample size calculation was not described in detail, and the statistical validity of 
the findings could therefore not be determined.  
 
Only prevalence data were available for all survey years, and results of intensity of infection 
are available from 2013 only. The actual effect of biennial MDA strategy could therefore not 
be evaluated, as prevalence may or may not follow changes in intensity of infection. 
Furthermore, data from 2011 and 2012 are limited or unavailable, and the increase in 
prevalence observed in five of the sentinel sites could not be further evaluated. The authors 
were not able to gather sufficient data from other sources in order to analyse the results. 
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Finally, the distribution of gender across age groups was not given and the impact of gender-
biased prevalences could have affected the results. 
 
Despite five rounds of MDAs from 2004 and 2012, data suggests that schistosomiasis is still 
prevalent in a majority of health districts in the country. In November 2013, the national 
NTD department at the Ministry of health in Burkina reviewed their control strategies for 
schistosomiasis. The Ministry concluded that the country will follow WHO guidelines, which 
suggest that control strategies should be implemented according to the district level 
prevalence of schistosomiasis (Table 2). A national elimination committee will be established 
in order to review the country’s strategies for ultimately eliminating schistosomiasis and 
other NTDs as a public health problem in Burkina (48). 
 
CONCLUSIONS 
The impact evaluation of five years of MDA of praziquantel in Burkina Faso from 2004 to 
2012 suggests that treatment has had a significant impact on reducing the prevalence of 
schistosomiasis. However, the prevalence of schistosomiasis still remains higher than 10% in 
8 of the 22 districts with sentinel sites, and there are important variations in prevalence and 
intensity of infection between districts and gender. Recently, Burkina has committed to 
follow WHO guidelines for the control and elimination of schistosomiasis, and a national 
elimination commitee will review the country’s strategies for ultimately eliminating 
schistosomiasis and other NTDs as a public health problem in Burkina Faso. Further and 
more detailed studies are needed in order to determine the effect of control strategies and 
future priorities for the control of schistosomiasis in Burkina Faso. 
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